Else Marit Inderberg
Position: Head of Immunomonitoring, PhD
Phone: +47 22 78 23 17

Project leader


2008-2011: PhD in Tumour Immunology (Faculty of Medicine,University of Oslo, Norway) “Cancer             vaccines and cancer-specific T-cell receptors; Development of novel immunotherapies”

2002-2005 : Diplôme EPHE Immunology (L’Ecole Pratique des Hautes Etudes, Sorbonne, Paris, France) «Development of an inducible melanoma model expressing a defined tumour antigen and its immunological characterisation »

1996-1998: BSc (Honours) Biochemistry University of Reading, UK


Research interests/projects:

Immunomonitoring facility for verification of treatment effects and mechanisms as well as biomarker discovery and development of novel immunotherapies

    • Detection of immune responses in patient samples pre- and post immunotherapy treatment.
    • Detection and discovery of immunotherapy biomarkers
    • Therapeutic TCR discovery and pre-clinical validation
    • Chimeric Antigen Receptors (CAR) discovery and pre-clinical validation
    • Discovery and pre-clinical validation of vaccination targets
    • Development of novel technologies to improve cell-based therapy

Work experience

2013-present:             Head of Immunomonitoring and Postdoctoral Fellow, Dept. of Cellular Therapy, OUS-Radiumhospitalet, Oslo, Norway          

2011-2012:      Research Fellow,  Institute for Cancer Research, OUS- Radiumhospitalet, Norway

2008-2011:      PhD student, Section for Immunotherapy, Institute for Cancer Research, OUS- Radiumhospitalet, Norway

2005–2008:     Research assistant, Dept. of Immunology, Institute for Cancer Research, OUS-Radiumhospitalet, Oslo, Norway

2002- 2005:     Research assistant, Centre of Immunology Marseille-Luminy, France

2001- 2002:     Research assistant, Institute for Cancer Research, Radiumhospitalet, Norway

1999- 2001:     Research Assistant/Laboratory manager   Dept. of Immunology, Rayne Institute, King’s College School of Medicine, London, UK 


  • F1000Research prize 2015 for outstanding presentation at PIVAC‐15 conference
  • Inven2 Innovation award 2014: "A universal killer-T cell for personalized medicine"




Author network for Else Marit Inderberg by COREMINE medical

Publications 2017

Inderberg EM, Wälchli S, Myhre MR, Trachsel S, Almåsbak H, Kvalheim G, Gaudernack G (2017)
T cell therapy targeting a public neoantigen in microsatellite instable colon cancer reduces in vivo tumor growth
Oncoimmunology, 6 (4), e1302631
PubMed 28507809

Josefsson SE, Huse K, Kolstad A, Beiske K, Pende D, Steen CB, Inderberg EM, Lingjærde OC, Østenstad B, Smeland EB, Levy R, Irish JM, Myklebust JH (2017)
T cells expressing checkpoint receptor TIGIT are enriched in follicular lymphoma tumors and characterized by reversible suppression of T-cell receptor signaling
Clin Cancer Res (in press)
PubMed 29217528

Lilleby W, Gaudernack G, Brunsvig PF, Vlatkovic L, Schulz M, Mills K, Hole KH, Inderberg EM (2017)
Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer
Cancer Immunol Immunother, 66 (7), 891-901
PubMed 28391357

Walseng E, Köksal H, Sektioglu IM, Fåne A, Skorstad G, Kvalheim G, Gaudernack G, Inderberg EM, Wälchli S (2017)
A TCR-based Chimeric Antigen Receptor
Sci Rep, 7 (1), 10713
PubMed 28878363

Publications 2016

Kyte JA, Gaudernack G, Faane A, Lislerud K, Inderberg EM, Brunsvig P, Aamdal S, Kvalheim G, Wälchli S, Pule M (2016)
T-helper cell receptors from long-term survivors after telomerase cancer vaccination for use in adoptive cell therapy
Oncoimmunology, 5 (12), e1249090
PubMed 28123886

Kyte JA, Aamdal S, Dueland S, Sæbøe-Larsen S, Inderberg EM, Madsbu UE, Skovlund E, Gaudernack G, Kvalheim G (2016)
Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells
Oncoimmunology, 5 (11), e1232237
PubMed 27999747

Publications 2015

Almåsbak H, Walseng E, Kristian A, Myhre MR, Suso EM, Munthe LA, Andersen JT, Wang MY, Kvalheim G, Gaudernack G, Kyte JA (2015)
Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model
Gene Ther, 22 (5), 391-403
PubMed 25652098

Publications 2014

Schiavelli R, Bonaventura R, Rial MC, Petrone H, Pujol GS, Gaite LJ, Acosta M, Gutierrez A, Acosta F, Valdez G, Raffaele P, Chanta G, Perez M, Potes L, Suso E, Cremades G, Ibañez J, Imperiali N, Luxardo R, Castellanos M, Maggiora E, Carreño CA, Cobos M, Marinic K, Sinchi JL et al. (2014)
First epidemiologic study in Argentina of the prevalence of BK viruria in kidney transplant patients
Transplant Proc, 46 (9), 3010-4
PubMed 25420812

Publications 2013

Vik-Mo EO, Nyakas M, Mikkelsen BV, Moe MC, Due-Tønnesen P, Suso EM, Sæbøe-Larssen S, Sandberg C, Brinchmann JE, Helseth E, Rasmussen AM, Lote K, Aamdal S, Gaudernack G, Kvalheim G, Langmoen IA (2013)
Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma
Cancer Immunol Immunother, 62 (9), 1499-509
PubMed 23817721

Publications 2012

Inderberg-Suso EM, Trachsel S, Lislerud K, Rasmussen AM, Gaudernack G (2012)
Widespread CD4+ T-cell reactivity to novel hTERT epitopes following vaccination of cancer patients with a single hTERT peptide GV1001
Oncoimmunology, 1 (5), 670-686
PubMed 22934259

Publications 2011

Huijbers IJ, Soudja SM, Uyttenhove C, Buferne M, Inderberg-Suso EM, Colau D, Pilotte L, Powis de Tenbossche CG, Chomez P, Brasseur F, Schmitt-Verhulst AM, Van den Eynde BJ (2011)
Minimal tolerance to a tumor antigen encoded by a cancer-germline gene
J Immunol, 188 (1), 111-21
PubMed 22140254

Suso EM, Dueland S, Rasmussen AM, Vetrhus T, Aamdal S, Kvalheim G, Gaudernack G (2011)
hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes
Cancer Immunol Immunother, 60 (6), 809-18
PubMed 21365467

Publications 2007

Shanker A, Verdeil G, Buferne M, Inderberg-Suso EM, Puthier D, Joly F, Nguyen C, Leserman L, Auphan-Anezin N, Schmitt-Verhulst AM (2007)
CD8 T cell help for innate antitumor immunity
J Immunol, 179 (10), 6651-62
PubMed 17982055

Publications 2006

Huijbers IJ, Krimpenfort P, Chomez P, van der Valk MA, Song JY, Inderberg-Suso EM, Schmitt-Verhulst AM, Berns A, Van den Eynde BJ (2006)
An inducible mouse model of melanoma expressing a defined tumor antigen
Cancer Res, 66 (6), 3278-86
PubMed 16540681

Publications 2003

Noble A, Leggat JA, Inderberg EM (2003)
CD8+ immunoregulatory cells in the graft-versus-host reaction: CD8 T cells activate dendritic cells to secrete interleukin-12/interleukin-18 and induce T helper 1 autoantibody
Immunology, 109 (4), 476-86
PubMed 12871213